Novartis announced that it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders.
Novartis acquired the company following receipt of results from the SUSTAIN study—a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive crises in patients with sickle cell disease (SCD). Results from the study will be presented at the American Society of Hematology (ASH) next month.
Results of SUSTAIN will be presented in the Plenary Scientific Session at the 58th American Society of Hematology (ASH) Annual Meeting.
This acquisition will help Novartis to broaden hematology pipeline.
Prior to the acquisition, Selexys Pharmaceutical Corporation was a privately held biopharmaceutical company headquartered in Oklahoma City, Oklahoma. Terms of the deal could total up to $665 million in upfront, acquisition and milestone payments.